Aicher, A.; Sindrilaru, A.; Crisan, D.; Thaiss, W.; Steinacker, J.; Beer, M.; Wiegel, T.; Scharffetter-Kochanek, K.; Beer, A.J.; Prasad, V.
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics 2022, 14, 1466.
https://doi.org/10.3390/pharmaceutics14071466
AMA Style
Aicher A, Sindrilaru A, Crisan D, Thaiss W, Steinacker J, Beer M, Wiegel T, Scharffetter-Kochanek K, Beer AJ, Prasad V.
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics. 2022; 14(7):1466.
https://doi.org/10.3390/pharmaceutics14071466
Chicago/Turabian Style
Aicher, Alexandra, Anca Sindrilaru, Diana Crisan, Wolfgang Thaiss, Jochen Steinacker, Meinrad Beer, Thomas Wiegel, Karin Scharffetter-Kochanek, Ambros J. Beer, and Vikas Prasad.
2022. "Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma" Pharmaceutics 14, no. 7: 1466.
https://doi.org/10.3390/pharmaceutics14071466
APA Style
Aicher, A., Sindrilaru, A., Crisan, D., Thaiss, W., Steinacker, J., Beer, M., Wiegel, T., Scharffetter-Kochanek, K., Beer, A. J., & Prasad, V.
(2022). Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics, 14(7), 1466.
https://doi.org/10.3390/pharmaceutics14071466
